PRINCIPAL INVESTIGATOR OF THE CANCER MOLECULAR TARGETS LABORATORYGroup leader at the Institut Hospital del Mar d’Investigacions Mèdiques (IMIM) (1999-present) and at Institut of Biomedical Research of Barcelona (IIBB)-CSIC (2018-present). This double affiliation is achieved through the Associated Unit IMIM-IIBB, a collaboration agreement between the two Institutes.
RESEARCH AREAS: Cellular and Molecular Biology, Oncology, Pancreatic Cancer, Translational Control, Galectins, Biomarkers, Molecular TherapeuticsMODELS : Cell Culture, Organoids, Genetically Engineered Mouse Models
Research interest in the last years is focused on the molecular mechanisms driving cancer onset and progression, with particular emphasis in pancreatic cancer. Among other findings, we have deciphered the molecular mechanism underlying tissue plasminogen activator (tPA) pathological functions, identify Galectin-1 as a novel target for cancer diagnosis and therapy and unveil new RNA translation-related mechanisms of regulation of gene expression in cancer.
Associated unit IMIM-IIBB (CSIC) Barcelona, Spain
at the Cancer Research Program at IMIM
Instituto Mario Negri (Dr. Elisabetta Dejana’s Lab) (Milan, Italy)
Hospital de La Princesa (Dr. Francisco Sánchez-Madrid Lab) (Madrid, Spain)
Institute of Biomedical Research (Dr. Amparo Cano´s Lab), University of Alcalá de Henares (Madrid, Spain).
Complutense University (Madrid, Spain)